# An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy

> **NCT02625090** · PHASE2 · TERMINATED · sponsor: **UCB Biopharma SRL** · enrollment: 42 (actual)

## Conditions studied

- Highly Drug-resistant Focal Epilepsy

## Interventions

- **DRUG:** UCB0942

## Key facts

- **NCT ID:** NCT02625090
- **Lead sponsor:** UCB Biopharma SRL
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-03
- **Primary completion:** 2020-11-24
- **Final completion:** 2020-11-24
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Based on available data, UCB has decided to stop development of padsevonil as adjunctive treatment of focal-onset seizure
- **Last updated:** 2022-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02625090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02625090, "An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02625090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*